Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06566248
- Locations
- 🇨🇳
Gansu Wuwei Tumour Hospital, Wuwei, Gansu, China
🇨🇳Zunyi Medical University Affiliated Hospital, Zunyi, Guizhou, China
🇨🇳The Fifth People's Hospital of Suzhou, Suzhou, Jiangsu, China
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06566586
- Locations
- 🇨🇳
Cancer Hospital Chinise Academy of Medical Sciences, BeiJing, Beijing, China
🇨🇳Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 542
- Registration Number
- NCT06561607
- Locations
- 🇨🇳
Zhangzhou Hospital in Fujian Province, Zhangzhou, Fujian, China
🇨🇳Gansu Wuwei Tumour Hospital, Wuwei, Gansu, China
🇨🇳Guigang City People'S Hospital, Guigang, Guangxi, China
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT06550713
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Peking University international Hospital, Beijing, Beijing, China
🇨🇳The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06527144
- Locations
- 🇨🇳
Fu Yang People'S Hospital, Fuyang, Anhui, China
🇨🇳ChongQing University Fuling Hospital, Chongqing, Chongqing, China
🇨🇳The Second Affiliated Hospital of Xiamen Medical College, Xiamen, Fujian, China
To Evaluate the Pharmacokinetics and Safety of TQD3524 for Injection in Renal Impairment Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06522945
A Clinical Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets
- Conditions
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06507891
- Locations
- 🇨🇳
Jingling Hospital, Nanjing, Jiangsu, China
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT06500091
- Locations
- 🇨🇳
Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Cancer Hospital Chinese Academy of Medical Science, BeiJing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06487416
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT06475599
- Locations
- 🇨🇳
Liuzhou People's Hospital, Liuzhou, Guangxi, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Hubei Cancer Hospital, Wuhan, Hubei, China